摘要
目的探讨罗沙司他治疗血液透析合并难治性肾性贫血的临床疗效。方法23例行规律血液透析治疗>1年且合并难治性肾性贫血的患者,在透析后均给予罗沙司他口服,治疗期间每2~4周监测血红蛋白(Hb)水平,每4周监测铁蛋白(SF)、C反应蛋白(CRP)、胆固醇(CHOL)、甘油三酯(TG)水平。比较治疗前后患者的Hb、SF、CRP、CHOL、TG水平变化。结果使用罗沙司他治疗后,患者的Hb水平较治疗前升高(P<0.05);SF、CRP水平较治疗前下降(P<0.05);胆固醇水平虽呈下降趋势,但治疗第4周的胆固醇水平与治疗前比较,差异无统计学意义(P>0.05),治疗第8周后的胆固醇水平与治疗前比较,差异有统计学意义(P<0.05);TG水平虽有变化,但差异不具有统计学意义(P>0.05)。结论罗沙司他可以有效提高血液透析合并难治性肾性贫血患者的Hb水平,同时能够降低SF、CRP水平,改善铁代谢,改善微炎症状态及脂质代谢。
Objective To investigate the clinical efficacy of roxadustat in the treatment of hemodialysis complicated with refractory renal anemia.Methods 23 of regular hemodialysis treatment>1 year and merger,in patients with refractory renal anemia were performed after dialysis Rosa his oral,monitor every 2~4 weeks during treatment level of hemoglobin(Hb),every 4 weeks monitoring ferritin(SF),c-reactive protein(CRP),cholesterol(CHOL),triglyceride(TG)levels.Hb,SF,CRP,CHOL and TG levels were compared before and after treatment.Results After roxadustat treatment,Hb level was higher than before treatment(P<0.05),SF and CRP levels were lower than before treatment(P<0.05).Although the cholesterol level showed a downward trend,there was no statistical significance in the cholesterol level at the 4th week of treatment compared with before treatment(P>0.05),and there was statistical significance in the cholesterol level after the 8th week of treatment compared with before treatment(P<0.05).Although TG level was changed,the difference was not statistically significant(P>0.05).Conclusion Roxadustat can effectively improve Hb level in hemodialysis patients with refractory renal anemia,while reducing SF and CRP levels,and improving iron metabolism,microinflammatory state and lipid metabolism.
出处
《浙江临床医学》
2021年第12期1782-1783,共2页
Zhejiang Clinical Medical Journal
作者简介
通信作者:秦玉萍。
